

# CITATION REPORT

List of articles citing

**Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?**

**DOI: 10.1093/eurheartj/ehr437**

**European Heart Journal, 2012, 33, 1049-57.**

**Source:** <https://exaly.com/paper-pdf/52816753/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1327-35	59.2	1858
17	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1082-94	12.3	143
16	The treatment of type 2 diabetes. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2014</b> , 111, 69-81; quiz 82	2.5	46
15	. <b>2014</b> ,		4
14	Cardiovascular toxicity, especially QT/QTc prolongation. <b>2014</b> , 193-228		
13	Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. <i>Value in Health</i> , <b>2014</b> , 17, 854-62	3.3	15
12	Oxidative stress in diabetes - circulating advanced glycation end products, lipid oxidation and vascular disease. <i>Annals of Clinical Biochemistry</i> , <b>2014</b> , 51, 125-7	2.2	14
11	Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. <i>Diabetes and Metabolism</i> , <b>2014</b> , 40, 176-85	5.4	51
10	Salutary cardiovascular effects of antidiabetic drugs: myth or fact?. <i>Journal of Hypertension</i> , <b>2015</b> , 33, 2198-9	1.9	2
9	Mechanisms of disease: paracrine effects of adipose tissue, progenitor cell function, and epigenetics of diabetic vascular disease. <i>European Heart Journal</i> , <b>2015</b> , 36, 765-7	9.5	2
8	Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. <i>Diabetes and Metabolism</i> , <b>2015</b> , 41, 195-201	5.4	21
7	Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective. <i>Current Diabetes Reports</i> , <b>2015</b> , 15, 87	5.6	18
6	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2016</b> , 2, 200-5	6.4	21
5	Cardiovascular outcome trials in type 2 diabetes: A critical analysis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2019</b> , 13, 300-305	8.9	1
4	Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals preferences. <i>Pharmacology Research and Perspectives</i> , <b>2021</b> , 9, e00750	3.1	1
3	Cardiovascular outcome trials in type 2 diabetes: what have we learned from the past and present?. <i>Journal of Diabetes Research &amp; Clinical Metabolism</i> , <b>2015</b> , 4, 3	0	
2	The diagnostic tactics of doctor of general practices regarding patient with carbohydrate metabolism disorders. <i>Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini</i> , <b>2016</b> , 2016, 98-104	0.1	

1 Acute myocardial infarction associated to DPP-4 inhibitors. *Heart, Lung and Vessels*, **2014**, 6, 180-6

4